Literature DB >> 23229506

Prostate cancer: Third time lucky? Dutasteride for tertiary prevention of prostate cancer.

Sarah Payton.   

Abstract

Entities:  

Year:  2012        PMID： 23229506     DOI： 10.1038/nrurol.2012.241

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Authors:  Fritz Schröder; Chris Bangma; Javier C Angulo; Antonio Alcaraz; Marc Colombel; Tom McNicholas; Teuvo L Tammela; Indrani Nandy; Ramiro Castro
Journal:  Eur Urol       Date:  2012-11-12       Impact factor: 20.096
  1 in total
  1 in total

1.  Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer.

Authors:  J Allaire; X Moreel; M-È Labonté; C Léger; A Caron; P Julien; B Lamarche; V Fradet
Journal:  Eur J Clin Nutr       Date:  2015-03-11       Impact factor: 4.016
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.